Senores Pharmaceuticals' Q2 FY 2025-26 Quarterly Results
- 06 Jan 2026
Result Summary
- Senores Pharmaceuticals Ltd reported a 18.3% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Sep (Q2 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 63.1%.
- Its expenses for the quarter were up by 10.2% QoQ and 46.2% YoY.
- The net profit increased 42.2% QoQ and increased 131.0% YoY.
- The earnings per share (EPS) of Senores Pharmaceuticals Ltd stood at 6.54 during Q2 FY 2025-26.
Financial Statments for Q2 FY 2025-26
Total Income | 167.17 | 141.35 | 102.49 | 18.3% | 63.1% |
Total Expenses | 126.54 | 114.86 | 86.54 | 10.2% | 46.2% |
Profit Before Tax | 40.63 | 26.49 | 15.95 | 53.4% | 154.7% |
Tax | 10.51 | 5.31 | 2.91 | 97.9% | 261.2% |
Profit After Tax | 30.12 | 21.18 | 13.04 | 42.2% | 131.0% |
Earnings Per Share | 6.54 | 4.60 | 3.92 | 42.2% | 66.8% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Senores Pharmaceuticals Ltd is a company engaged in the pharmaceutical industry, primarily involved in the development, manufacturing, and marketing of pharmaceutical products. The company focuses on producing a wide range of generic drugs that cater to various therapeutic segments. As with many companies in the pharmaceutical sector, Senores Pharmaceuticals Ltd is likely involved in ongoing research and development efforts to innovate and expand its product offerings. However, specific recent major developments and detailed product information are not available in the provided data.
Revenue
In the second quarter of fiscal year 2026 (Q2FY26), Senores Pharmaceuticals Ltd reported a total income of ₹167.17 crores. This represents an 18.3% increase from the previous quarter (Q1FY26), where the total income was ₹141.35 crores. When compared to the second quarter of fiscal year 2025 (Q2FY25), there is a significant year-over-year growth of 63.1%, as the total income in Q2FY25 was ₹102.49 crores. This substantial increase indicates a strong revenue performance over the periods considered.
Profitability
For Q2FY26, Senores Pharmaceuticals Ltd achieved a profit before tax of ₹40.63 crores, which marked a 53.4% increase from ₹26.49 crores reported in the previous quarter. Year-over-year, the profit before tax rose by 154.7% from ₹15.95 crores in Q2FY25. The company's tax expenses in Q2FY26 were ₹10.51 crores, which rose by 97.9% from the previous quarter and by 261.2% from the same quarter last year. The resulting profit after tax for Q2FY26 amounted to ₹30.12 crores, showing a 42.2% increase quarter-over-quarter and a 131.0% rise year-over-year. The earnings per share in Q2FY26 were ₹6.54, reflecting similar growth trends in profitability metrics.
Operating Metrics
During Q2FY26, Senores Pharmaceuticals Ltd recorded total expenses of ₹126.54 crores, which represents a 10.2% increase from the previous quarter's expenses of ₹114.86 crores. Compared to Q2FY25, the total expenses increased by 46.2% from ₹86.54 crores. This indicates that while expenses have risen, the company has managed to achieve higher profitability and revenue growth. The earnings per share for Q2FY26 were at ₹6.54, compared to ₹4.60 in Q1FY26 and ₹3.92 in Q2FY25, demonstrating a consistent upward trend in shareholder returns.